Business Context and Reporting Period
Company: Verastem, Inc. (VSTM)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Verastem is a biopharmaceutical company focused on RAS/MAPK pathway-driven cancers. In May 2025, the company received FDA accelerated approval for AVMAPKI FAKZYNJA CO-PACK (avutometinib capsules; defactinib tablets) for the treatment of adults with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC). The company also advanced its pipeline, including the KRAS G12D inhibitor VS-7375, and completed enrollment in the Phase 3 RAMP 301 confirmatory trial.
Key Financial Metrics
| Metric (in millions) | 2025 | 2024 |
|---|---|---|
| Total Revenue | $30.9 | $10.0 |
| Net Product Revenue | $30.9 | $0.0 |
| Net Loss | $(209.5) | $(130.6) |
| Research & Development (R&D) Expense | $114.6 | $81.3 |
| Selling, General & Administrative (SG&A) Expense | $81.1 | $43.6 |
| Cash and Cash Equivalents (Dec 31, 2025) | $205.0 | $88.8 |
| Long-Term Debt (Fair Value) | $76.3 | $40.7 |
| Accumulated Deficit | $(1,165.0) | $(955.5) |
Note: 2024 revenue consisted entirely of a $10.0 million milestone payment from Secura Bio regarding the sale of COPIKTRA assets. 2025 revenue is derived from commercial sales of AVMAPKI FAKZYNJA CO-PACK.
Material Changes vs. Prior Period
- Revenue Shift: The company transitioned from milestone-based revenue in 2024 to product revenue in 2025 following the May 2025 FDA approval and commercial launch of AVMAPKI FAKZYNJA CO-PACK.
- Expense Growth: Operating expenses increased significantly to $201.0 million in 2025 from $125.0 million in 2024. This was driven by a $33.3 million increase in R&D (due to the RAMP 301 trial and VS-7375 development) and a $37.5 million increase in SG&A (primarily launch-related consulting and professional fees).
- Debt Restructuring: In January 2025, the company entered a new Note Purchase Agreement for up to $150.0 million, initially drawing $75.0 million. Concurrently, it repaid its prior Oxford Loan Agreement in full, resulting in a $1.8 million loss on debt extinguishment.
- Non-Cash Charges: The 2025 net loss included a $27.5 million mark-to-market loss on warrant liabilities and a $12.8 million change in fair value of Notes, compared to $19.1 million and $0.0 million respectively in 2024.
Guidance, Outlook, and Risks
Outlook and Milestones
- RAMP 301 Trial: Enrollment for the Phase 3 confirmatory trial was completed ahead of schedule in October 2025, with an additional 29 patients added in December 2025. Topline data is expected in mid-2027.
- VS-7375: The Phase 1/2 trial for the KRAS G12D inhibitor is ongoing. The company expects to report early dose-escalation data in the first half of 2026.
- Liquidity: Management expects cash resources of $205.0 million (as of Dec 31, 2025), plus $29.4 million received from warrant exercises in January 2026, combined with product revenue, to fund operations for at least 12 months from the filing date.
Risks and Contingencies
- Accelerated Approval Requirements: The FDA requires the completion of the RAMP 301 trial to confirm clinical benefit. Failure to confirm benefit could result in withdrawal of the product from the market.
- Capital Needs: The company has incurred significant losses since inception and may require additional funding to support commercialization and pipeline development. Failure to raise capital could force delays or reductions in programs.
- Regulatory and Pricing: Risks include potential changes in healthcare policy, drug pricing reforms (e.g., Inflation Reduction Act), and the ability to obtain reimbursement from third-party payors.
- Intellectual Property: The company relies on licenses from Pfizer (defactinib) and Chugai (avutometinib). Termination of these agreements would materially harm the business.
Investor Verification Checklist
- Commercial Adoption: Verify the rate of prescription uptake and market penetration of AVMAPKI FAKZYNJA CO-PACK in the rare LGSOC population.
- RAMP 301 Progress: Monitor patient follow-up and data maturity for the Phase 3 confirmatory trial, as this is critical for full FDA approval.
- Liquidity Runway: Confirm the sufficiency of cash reserves against the burn rate, considering the high costs of commercialization and ongoing clinical trials.
- VS-7375 Data: Review the safety and efficacy data from the Phase 1/2 trial expected in H1 2026 to assess the potential of the KRAS G12D pipeline.
- Debt Covenants: Review the terms of the Note Purchase Agreement, specifically the revenue participation percentage (1.00% to 2.00% of net sales) and conditions for additional drawdowns.